TIDES USA 2023 witnessed the largest turnout in the history of the event, welcoming more than 1,700 attendees from over 500 different companies across the globe. The conference took place May 7-10 in San Diego, Calif. Thank you for making TIDES USA 2023 the largest and most renowned event dedicated to accelerating oligonucleotide and peptide therapeutics to market.
The conference featured more than 150 industry leaders who spoke across six comprehensive tracks, discussing various aspects of therapeutic development. These tracks included “Oligonucleotide Chemistry, Manufacturing & Controls,” which focused on the manufacturing and quality control of oligonucleotides, and “Oligonucleotide Discovery, Preclinical and Clinical,” which explored the process of discovering and developing oligonucleotide therapeutics. Another track, “Peptide Chemistry, Manufacturing & Controls,” delved into the manufacturing and quality aspects of peptide-based drugs, while the “Peptide Discovery, Preclinical and Clinical” track highlighted the journey from discovery to clinical development of peptide therapeutics. Additionally, the “mRNA Therapeutics/Vaccines & Genome Editing” track examined the advancements and applications of mRNA-based therapies and genome editing techniques.
Lastly, the “Drug Delivery Innovation” track focused on the challenges and innovations in delivering macromolecules for therapeutic purposes. Collectively, these six themes provided a comprehensive overview of the key areas in therapeutic development, fostering collaboration and knowledge exchange among researchers and industry professionals.
This eBook showcases significant discussions that occurred during TIDES USA 2023, featuring Intellia Therapeutics, Novo Nordisk, Alnylam Pharmaceuticals, and more.
We hope to see you next year at TIDES USA 2024, May 14-17, in Boston, Mass.